Journals / Turkish Journal of Hematology / 2013 / Cilt: 30 - Sayı: 3

Ratlarda kemik iliği nakli sonrası gelişen graft versus host hastalığında multipotent mezenşimal stromal hücrelerin immünsupresif etkileri

Immunosuppressive effects of multipotent mesenchymal stromal cells on graft-versus-host disease in rats following allogeneic bone marrow transplantation

Pages
256–262
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Our results suggest that clinical use of MSCs in both prophylaxis against and treatment of established GVHD is effective.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Graft-versus-host disease (GVHD) is a major obstacle to successful allogeneic bone marrow transplantation (allo-BMT).
📊
Key Findings & Data:While multipotent mesenchymal stromal cells (MSCs) demonstrate alloresponse in vitro and in vivo, they also have clinical applications toward prevention or treatment of GVHD.
💡
Conclusion & Impact:Conclusion: Our results suggest that clinical use of MSCs in both prophylaxis against and treatment of established GVHD is effective.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Graft-versus-host disease (GVHD) is a major obstacle to successful allogeneic bone marrow transplantation (allo-BMT). While multipotent mesenchymal stromal cells (MSCs) demonstrate alloresponse in vitro and in vivo, they also have clinical applications toward prevention or treatment of GVHD. The aim of this study was to investigate the ability of MSCs to prevent or treat GVHD in a rat BMT model. Materials and Methods: The GVHD model was established by transplantation of Sprague Dawley rats’ bone marrow and spleen cells into lethally irradiated (950 cGy) SDxWistar rat recipients. A total of 49 rats were randomly assigned to 4 study and 3 control groups administered different GVHD prophylactic regimens including MSCs. After transplantation, clinical GVHD scores and survival status were monitored. Results: All irradiated and untreated control mice with GVHD died. MSCs inhibited lethal GVHD as efficiently as the standard GVHD prophylactic regimen. The gross and histopathological findings of GVHD and the ratio of CD4/CD8 expression decreased. The subgroup given MSCs displayed higher in vivo proportions of CD25+ T cells and plasma interleukin-2 levels as compared to conventional GVHD treatment after allo-BMT. Conclusion: Our results suggest that clinical use of MSCs in both prophylaxis against and treatment of established GVHD is effective. This study supports the use of MSCs in the prophylaxis and treatment of GVHD after allo-BMT; however, large scale studies are needed.

Özet

Amaç: Graft versus host hastalığı (GVHH) , başarılı bir kemik iliği nakli için önemli bir engel oluşturmaktadır. Multipotent mezenşimal stromal hücrelerin (MSH) immünsupresif etkileri, in vivo ve in vitro olarak gösterilmiş olmakla birlikte, GVHH’ nı önleme yönünde klinik uygulamalarda bulunmaktadır . Gereç ve Yöntemler: Bu çalışmanın amacı ratlarda kemik iliği nakli sonrası oluşturulan GVHH’nı önleme ve tedavi etmede MSH nin etkinliğinin incelenmesidir. Bu amaçla 49 Sprague Dawley cinsi rat rastegele 4 çalışma, 3 kontrol grubuna ayrılmış ve gruplara MSH de içeren farklı GVHH önleyici tedaviler uygulanmıştır. Kemik iliği nakli sonrası GVHH skorlaması ve yaşama süreleri incelenmiştir. Bulgular: Tüm ışınlanmış ve önleyici tedavi verilmemiş ratlar ölmüştür. MSH nin önleyici uygulamaları, standart GVHD önleyici tedavileri kadar etkin bulunmuştur. MSH uygulamaları, GVHH nın gözlemsel ve histolojik bulgularını ve CD4+/CD8+ oranını azaltmaktadır.Ayrıca MSH uygulanan gruplarda CD25+ T hücrelerinin in vivo oranıda daha yüksek olup, Allojeneik kemik iliği nakli sonrası standart GVHH tedavisi uygulananlara göre plazma İnterlökin-2 seviyesinin daha yüksek olarak saptanmıştır. Sonuç: Bulgularımız MSH uygulamasının, GVHH nın hem önlenme hem de tedavi edilmesinde etkin olduğunu göstermiştir. Ancak bu bulguların geniş ölçekli çalışmalarla desteklenmesi gerekmektedir.

🔖

Cite This Article

NEVRUZ, O., AVCU, F., URAL, A. U., PEKEL, A., DİRİCAN, B., SAFALI, M., AKDAĞ, E., BEYZADEOĞLU, M. M., İDE, T., ŞENGÜL, A. (2013). Ratlarda kemik iliği nakli sonrası gelişen graft versus host hastalığında multipotent mezenşimal stromal hücrelerin immünsupresif etkileri. Turkish Journal of Hematology, Cilt: 30 - Sayı: 3, 256–262. https://ajindex.com/articles/412624

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991
  2. 200 150 2. Tabbara IA, Zimmerman K, Morgan C, Nahleh Z. Allogeneic hematopoietic stem cell transplantation: complications and results. Arch Intern Med 2002
  3. Deeg HJ. How I treat refractory acute GVHD. Blood 2007
  4. Kadiyala S, Young RG, Thiede MA, Bruder SP. Culture expanded canine mesenchymal stem cells possess osteochondrogenic potential in vivo and in vitro. Cell Transplant 1997
  5. 6,125-134. 5. Pittenger MF Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science 1999
  6. Fibbe WE, Nauta AJ, Roelofs H. Modulation of immune responses by mesenchymal stem cells. Ann NY Acad Sci 2007
  7. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003
  8. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005
  9. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, Mao N. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005
  10. Aggarwal S, Pittenger MF Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005
  11. Fang B, Song Y, Liao L, Zhang Y, Zhao RC. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proc 2007
  12. Akpek G. Graft versus host disease (GVHD) an evidence based management guidelines. Turk J Haematol 2003
  13. Ram R, Gafter-Gvili A, Yeshurun M, Paul M, Raanani P, Shpilberg O. Prophylaxis regimens for GVHD: systematic review and meta-analysis. Bone Marrow Transplant 2009
  14. Van Lint MT, Milone G, Leotta S, Uderzo C, Scimè R, Dallorso S, Locasciulli A, Guidi S, Mordini N, Sica S, Cudillo L, Fagioli F Selleri C, Bruno B, Arcese W, Bacigalupo A. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006
  15. Couriel DR, Saliba R, Escalón MP, Hsu Y, Ghosh S, Ipp